Degarelix
FDA ApprovedAn FDA-approved GnRH antagonist used for prostate cancer. Unlike GnRH agonists, it immediately suppresses testosterone without an initial flare.
Reproductive HealthHormonal Health
Half Life
~28 days (depot form)
Time to Results
Days
Administration
SubQ injection (depot)
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyMonthly depot
Cost$$$
🐾 Griffin Says...
Important from an educational standpoint because it shows the difference between GnRH agonists and antagonists. Antagonists block immediately without the initial flare that agonists produce. This distinction matters a lot clinically for prostate cancer management.
Benefits
- Rapid testosterone suppression
- No testosterone flare (vs agonists)
- Hormone-sensitive cancer management
Best For
- Hormone-sensitive cancer research
- Advanced hormonal research
Body Systems
ReproductiveEndocrine
Mechanisms of Action
- GnRH receptor antagonist (not agonist)
- Immediately blocks receptor
- Rapid testosterone reduction within days
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Injection site reactions | Very Common | Mild-Moderate |
| Hot flashes | Very Common | Mild |
| Weight gain | Common | Mild |
Contraindications
Not for general use, clinical indication required
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator